RD

RadNet, Inc.

RDNTHealthcareNASDAQ

Diagnostics & Research

PriceMA150MA200
Loading chart…
End-of-day data · ScananceOpen live chart on TradingView ↗
Indicator snapshot
MA150+20.40%
$62.88

Price above medium-term moving average.

MA200+14.51%
$66.10

Above long-term trend line.

RSI-14neutral
59.3

Balanced. Not overbought, not oversold.

MACDnegative
-0.5320

Histogram negative, downward momentum.

Financials · Annual
Revenue
$2.04B
+11.5% YoY
Net Income
-$18.7M
-767.8% YoY
EBITDA
$313.8M
-2.9% YoY
Free Cash Flow
$157.7M

Scan Results

Daily timeframe
DateIndicatorDetails
Aug 27 MACD Negative CrossoverHistogram -0.1602, negative momentum
Aug 26CONFIRMED MACD Negative CrossoverHistogram -0.0807, negative momentum
RSI OverboughtRSI 71.0, above 70, stock may be overbought
About RadNet, Inc.

Headquartered within the healthcare sector, RadNet, Inc. focuses on Diagnostics & Research services and products. RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States and internationally. With a market capitalization of $5.96B, it sits in mid-cap territory. The company operates in two segments, Imaging Centers and Digital Health.

Where RDNT stands vs its 150-day and 200-day moving averages

As of the August 27, 2026 close, RDNT finished 21.79% above its 150-day moving average ($62.79) and 15.60% above its 200-day moving average ($66.15). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.

Is RDNT overbought or oversold?

At the August 27, 2026 close, RDNT's RSI(14) was 68.3, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.

Key stats
Market Cap$5.96B
Fwd P/E85.38
EPS$-0.26
Beta1.38
52W Change+4.5%
ROE1.5%
Analysis

RadNet, Inc. carries $2.18B in total debt against $726.3M in cash reserves — debt is roughly 3.0x the cash position. Managing this leverage effectively will be important for long-term financial stability. Free cash flow comes in at $157.7M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of 1.5% points to modest capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 1.7% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $1.43B (2022) to $2.04B (2025), reflecting a 43% increase over the period.

As with any equity investment, RDNT carries market risk, sector-specific risk, and company-specific risk that investors should evaluate in the context of their own portfolios. No single metric tells the full story. Reviewing RDNT's risk profile alongside its fundamentals and technical indicators provides a more complete picture.

Links
More Healthcare stocks
Browse all stocks →
Not financial advice. Scanance shows end-of-day technical indicators (not real-time prices) for information only. Results can be wrong; past performance does not guarantee future results.PrivacyTerms